Interest grows in 3 experimental Covid treatments
Two months ago, vaccines were seen as the great hope to end Covid-19. Now, as the virus continues to mutate, interest in emerging Israeli treatments is growing fast.
Two months ago, vaccines were seen as the great hope to end Covid-19. Now, as the virus continues to mutate, interest in emerging Israeli treatments is growing fast.
Experimental Covid drug cures 30 out of 30 moderate to severe cases in Phase I clinical trial at Israeli hospital. Second new drug also shows promise.
Clinical trial shows promise of Enlivex’s immunotherapy drug Allocetra engineered from healthy human donor cells.
Innoviz and StoreDot, each with technologies for the vehicles of tomorrow, lead the pack with funding infusions of $65m and $60m, respectively.
The drug makes the donor tissue less likely to destroy the patient’s organs, while allowing the regular immune activity against the cancer.